Article

Pharmaceutical Executive

FDA Releases Guidance on Biosimilar Naming

Author(s):

August 28, 2015.

The long-awaited draft guidance on biosimilar naming has been posted by FDA, reports BioPharm International's Randi Hernandez.

Within the document, the agency suggests naming follow-on biologics by a common nonproprietary name, followed by a suffix that will identify the manufacturer of the particular biosimilar. The naming scheme is consistent with the way the agency labeled Zarxio (filgrastim-sndz), the first biosimilar product to be approved by FDA. The naming convention will be used for all future biosimilar products and will also be applied retroactively, meaning the naming convention will apply to biologic products that are already on the market.

For more on this story, read the BioPharm International report here.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Videos
Gen Li
Gen Li
Ted Sweetser
Ted Sweetser
Ted Sweetser